MedTrace Logo

Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis

NCT02133807 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-05-12

No results posted yet for this study

Summary

To evaluate whether specific lipoprotein(a) apheresis on the top of optimal medical therapy could affect atherosclerotic disease burden in coronary and carotid arteries of coronary heart disease patients with elevated Lp(a) levels.

Conditions

Interventions

PROCEDURE

Specific Lp(a) apheresis

Specific Lp(a) apheresis procedures were carried out weekly with "Lp(a) Lipopak" columns (POCARD Ltd., Moscow, Russia) according to the standard protocol

Sponsors & Collaborators

  • Clinical Diagnostic Center MEDSI

    collaborator UNKNOWN

  • Moscow State Government

    collaborator UNKNOWN

  • Russian Cardiology Research and Production Center

    lead OTHER

Principal Investigators

  • Sergei Pokrovsky, PhD, DSc · Russian Cardiology Research and Production Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-03-31
Completion
2012-06-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02133807 on ClinicalTrials.gov